MSC vs exosomes for Parkinson's Disease: what the registries show
For Parkinson's Disease, the registry holds 19 MSC records against 5 exosomes records. MSC carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | exosomes |
|---|---|---|
| Registered studies | 19 | 5 |
| Recruiting now | 1 | 2 |
| Phase 3 or 4 records | 1 | 0 |
| Completed | 4 | 1 |
| Stopped early | 1 | 0 |
| Countries with sites | 8 | 5 |
| Median planned enrolment | 20 | 120 |
| First registration year | 2,009 | 2,013 |
The condition underneath the comparison
Parkinson's involves loss of dopaminergic neurons in the substantia nigra, making it one of the few neurodegenerative conditions with a defined cell type to replace. Pluripotent-derived dopaminergic grafts are a serious, decades-long research programme with surgical delivery — categorically different from intravenous infusions marketed for Parkinson's.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
exosomes: what it is
Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.
Maturity difference
MSC has 1 Phase 3/4 records and 4 completed studies; exosomes has 0 and 1. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05152394 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease | Phase 1 | Recruiting | 20 | The Foundation for Orthopaedics and Regenerative Medicine | 2024-08-17 |
| NCT04146519 — Parkinson's Disease Therapy Using Cell Technology | Phase 2, Phase 3 | Unknown | 50 | Belarusian Medical Academy of Post-Graduate Education | 2017-07-01 |
| NCT07471230 — Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism | Phase 2 | Not Yet Recruiting | 120 | Biocells Medical | 2026-11-23 |
| NCT06858254 — Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism | Phase 1, Phase 2 | Not Yet Recruiting | 60 | Apeiron Research Center | 2025-04-01 |
| NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) | Phase 2 | Completed | 24 | Hope Biosciences Research Foundation | 2021-06-28 |
Leading exosomes studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05152394 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease | Phase 1 | Recruiting | 20 | The Foundation for Orthopaedics and Regenerative Medicine | 2024-08-17 |
| NCT07679256 — Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application | n/a | Recruiting | 700 | Fujian Medical University Union Hospital | 2024-01-01 |
| NCT07471230 — Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism | Phase 2 | Not Yet Recruiting | 120 | Biocells Medical | 2026-11-23 |
| NCT07521384 — Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy | n/a | Enrolling By Invitation | 36 | Healing Hope International | 2026-06-01 |
| NCT01860118 — LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease | n/a | Completed | 601 | University of Alabama at Birmingham | 2013-01 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than exosomes for Parkinson's Disease?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 19 vs 5 registered records (2026-08-29).
Which has more late-stage research for Parkinson's Disease?
MSC: 1 Phase 3/4 records. exosomes: 0.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.